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A Corrigendum on
Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface
Localization and Antibody-Mediated Killing in Most Meningococcal Isolates
by da Silva, R. A. G., Karlyshev, A. V., Oldfield, N. J., Wooldridge, K. G., Bayliss, C. D., Ryan, A., et al.
(2019). Front. Microbiol. 10:2847. doi: 10.3389/fmicb.2019.02847
In the original article, the labelling of “Class 2” and “Class 3” isolates was switched erroneously in
Table 2 and Figure 9B. The corrected Table 2 and Figure 9 appear below.
Further, the year the Trumenba vaccine was licensed is incorrectly provided as “2015” and
should be “2014”.
A correction has been made to the Introduction, paragraph three.
“Through an accelerated approval process, both Trumemba (Pfizer) and Bexsero (GSK) were
licensed by the FDA in 2014 and 2015 respectively for immunization to prevent invasive disease
by meningococcal group B in the United States in individuals 10 to 25 years of age. Trumenba
comprises two recombinant FHbps, one from subfamily A, the other from subfamily B, both
containing the lipid moiety found in the native protein (Fletcher et al., 2004; Gandhi et al., 2016).
A recombinant non-lipidated form of FHbp from subfamily B is also one of the antigens of the
Bexsero vaccine (GSK) (Vernikos and Medini, 2014) licensed for infants from 2 months of age in
Europe in 2013 and, like Trumenba, now licensed globally (Basta and Christensen, 2016).”
The authors apologize for these errors and state that this does not change the scientific
conclusions of the article in any way. The original article has been updated.
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da Silva et al. Most Meningococci Present Non-lipidated FHbp
TABLE 2 | MenB invasive isolates used in this study.
Class Isolate number Isolate, full name
1 – MC58
1 H44/76
2 M10_240684
3 M10_240701
4 M02_241729
3 5 M10_240579
6 M13_240525
7 M04_241215
8 M11_241066
9 M13_240614
2 – L91543
10 M10_240750
11 M13_240675
12 M11_240236
13 M12_240006
4 14 M11_241033
15 M14_240367
16 M02_240210
17 M11_240077
18 M13_240486
The SP class is indicated for each isolate.
FIGURE 9 | Comparison of biological activities of unprocessed and processed surface-localized FHbp. (A) FACS analysis with Mab JAR4. A representative flow
cytometry plot for each isolate is shown. The read-outs from negative control samples, cells incubated with secondary antibody only (left peak) were gated (as shown
by the arrows). The read-outs from samples incubated with both primary and secondary antibody were overlaid. (B) The number of JAR4 antibody molecules bound
per cell (ABC) and corresponding prediction for successful killing in SBA assays is denoted by +. The actual percentage killing for each isolate with Mabs JAR4, JAR5
and human complement is shown. The mean ABC for each isolate was derived from three independent FACS experiments and the mean percentage killing derived
from four independent SBA experiments, each with two technical replicates. The binding of fH to cells. Values show the Relative Mean of Fluorescence Intensity (rMFI)
for total fluorescing cells after incubation with fH and anti-fH PE-conjugated antibody. The values were normalized against the negative control of cells alone incubated
with antibody. (C) Pooled data for class 1 and non-class 1 isolates, excluding the outliers. Values were analyzed by unpaired t-tests with Welsch’s correction. Columns
represent mean ± SEM, *p < 0.05 vs. class 1.
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